FDMT · 4D Molecular Therapeutics, Inc. · Documents
$12.55
+0.59 (+4.94%)
At close · Oct 28
Return incl. dividend (before tax)
Market Cap
$863.27M
Shares
72.18M
Volume · Oct 28
1.19M
Avg daily vol (3M)
996.05K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | 4D Molecular Therapeutics said the first patients were enrolled across multiple sites in the 4SIGHT Phase 3 trial of 4D-150 for diabetic macular edema. Two-year SPECTRA data showed a 61% overall treatment-burden reduction for the Phase 3 dose. | 2026-09-28 | — | |
| Investor Event Transcript | — | 2026-09-14 | 2026-09-30 | |
| 10-Q | — | 2026-08-13 | 2026-06-30 | |
| 8-K | — | 2026-08-13 | — | |
| 8-K | — | 2026-07-20 | 2026-07-18 | |
| 8-K | — | 2026-06-29 | 2026-06-24 | |
| 8-K | — | 2026-06-22 | 2026-06-17 | |
| Investor Event Transcript | — | 2026-06-09 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-06-03 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-19 | 2026-06-30 | |
| Investor Event Transcript | — | 2026-05-13 | 2026-06-30 | |
| 8-K | — | 2026-05-07 | — | |
| S-3 | — | 2026-05-07 | — | |
| 10-Q | — | 2026-05-07 | 2026-03-31 | |
| DEF 14A | — | 2026-04-28 | 2026-06-17 | |
| ARS | — | 2026-04-28 | 2025-12-31 | |
| DEFA14A | — | 2026-04-28 | — | |
| 8-K | — | 2026-03-30 | 2026-03-25 | |
| 8-K | — | 2026-03-18 | — | |
| 10-K | — | 2026-03-18 | 2025-12-31 | |
| Investor Event Transcript | — | 2026-03-12 | 2026-03-31 | |
| Investor Event Transcript | — | 2026-03-03 | 2026-03-31 | |
| 8-K | — | 2026-01-26 | 2026-01-22 | |
| 8-K | — | 2026-01-07 | 2025-12-31 | |
| 8-K | — | 2025-12-10 | — | |
| Investor Event Transcript | — | 2025-11-18 | 2025-12-31 | |
| 8-K | — | 2025-11-17 | — | |
| 10-Q | — | 2025-11-10 | 2025-09-30 | |
| 8-K | — | 2025-11-10 | — | |
| 8-K | — | 2025-11-07 | 2025-11-06 | |
| 8-K | — | 2025-11-06 | — | |
| 8-K | — | 2025-10-31 | — | |
| 8-K | — | 2025-10-02 | 2025-09-30 | |
| 8-K | — | 2025-08-11 | — | |
| 10-Q | — | 2025-08-11 | 2025-06-30 | |
| 8-K | — | 2025-07-02 | 2025-06-27 | |
| 8-K | — | 2025-06-20 | 2025-06-17 | |
| 8-K | — | 2025-05-08 | — | |
| 10-Q | — | 2025-05-08 | 2025-03-31 | |
| DEF 14A | — | 2025-04-29 | 2025-06-17 | |
| ARS | — | 2025-04-29 | 2024-12-31 | |
| DEFA14A | — | 2025-04-29 | — | |
| 8-K | — | 2025-02-28 | — | |
| 10-K | — | 2025-02-28 | 2024-12-31 | |
| 8-K | — | 2025-02-10 | 2025-02-08 | |
| 8-K | — | 2025-01-10 | — | |
| 8-K | — | 2024-12-11 | 2024-12-06 | |
| 8-K | — | 2024-11-13 | — | |
| 10-Q | — | 2024-11-13 | 2024-09-30 | |
| 8-K | — | 2024-09-18 | — |
Showing 1–50 of 121 filings
Key facts
CIK
1650648
CUSIP
35104E100
13F (30d)
20 filings
20 filers
Visit website
Investor relations